Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.64 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.53 |
| ▸ | CDK2 | P24941 | 2/20 | 0.53 |
| ▸ | CDK9 | P50750 | 2/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.52 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.51 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.51 |
| ▸ | FEN1 | P39748 | 1/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.48 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6581932 | 0.81 | MAPK14 (0.51) | ADORA1CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL17200126 | 0.80 | HSP90AA1 (0.66) | CCNT1CCNA2CDK2CDK9MAPK14 | |
| SCHEMBL7222483 | 0.80 | ADORA1 (0.75) | ADORA1MAPK14CSNK1ECDK5CDK5R1 | |
| SCHEMBL7210550 | 0.80 | ADORA1 (0.75) | ADORA1MAPK14CSNK1ECDK5CDK5R1 | |
| SCHEMBL1645470 | 0.78 | CCNT1 (0.53) | ADORA1CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL9956075 | 0.78 | ADORA1 (0.77) | ADORA1FEN1ADORA2AKMT2AMAPK1 | |
| SCHEMBL28937364 | 0.77 | ADORA1 (0.62) | ADORA1ADORA2AKMT2ARPS6KA3 | |
| SCHEMBL22789740 | 0.76 | MAP4K4 (0.64) | CCNT1CCNA2CDK2CDK9MAPK14 | |
| SCHEMBL14519513 | 0.75 | MAPK14 (0.55) | CCNT1CCNA2CDK2CDK9MAPK14 | |
| SCHEMBL23275774 | 0.74 | CDK5 (0.44) | ADORA1CCNT1CCNA2CDK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655340-B1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2015-01-21 | — | — | EP | disclosed |
| US-8901147-B2 | Bi-heteroaryl compounds as Vps34 inhibitors | NOVARTIS AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-20140155402-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | disclosed |
| US-20130338159-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2013-12-19 | — | — | US | disclosed |
| EP-2655340-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | Novartis AG (CH) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085815-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155402-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | VPS35, VPS26B, VPS26A | ADORA1 3948/4885CCNT1 2833/4885CCNA2 3470/4885 |
| US-20130338159-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | VPS35, VPS26B, VPS26A | ADORA1 3909/4885CCNT1 2820/4885CCNA2 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.